Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has drawn a 'Buy' rating from Rodman & Renshaw, which initiated coverage on the company with an $8.00 price target. The rating is based on the potential of Lucid-MS, a drug candidate described as a potentially first-in-class non-immunomodulatory small molecule. Lucid-MS is being developed to address neurodegeneration and disability progression in progressive multiple sclerosis, a condition where therapeutic options remain limited. The firm's $8.00 price target reflects its valuation of Quantum BioPharma's development pipeline.
The initiation of coverage by a major financial firm highlights the growing interest in Quantum BioPharma's lead compound. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, and the potential to halt or reverse this process could represent a significant advancement in the treatment of the disease. Progressive multiple sclerosis, in particular, has been a challenging area for drug development, with few approved therapies that effectively slow disability progression.
The 'Buy' rating and price target from Rodman & Renshaw may signal confidence in Quantum BioPharma's approach and its potential to bring a novel therapy to patients. The company is dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS.
In addition to its work on Lucid-MS, Quantum BioPharma has also developed UNBUZZD(TM), a product aimed at addressing alcohol misuse. The company spun out the OTC version of UNBUZZD(TM) to Unbuzzd Wellness Inc. (UWI), led by industry veterans, while retaining ownership of 19.48% of UWI as of June 30, 2026. The agreement includes royalty payments of 7% of sales from UNBUZZD(TM) until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The news of the 'Buy' rating comes at a time when the biopharmaceutical industry is seeing increased focus on treatments for neurodegenerative diseases. Multiple sclerosis affects millions worldwide, and progressive forms of the disease present a particularly high unmet medical need. If Lucid-MS continues to show promise in clinical trials, it could become a valuable addition to the treatment landscape.
The price target of $8.00 suggests that Rodman & Renshaw sees significant upside potential from current trading levels, based on their analysis of the company's pipeline and the market opportunity for Lucid-MS. For investors, this endorsement may provide a level of confidence in the company's strategic direction and the potential of its lead drug candidate.
Quantum BioPharma's stock is publicly traded on NASDAQ under the ticker QNTM and on the Canadian Securities Exchange under the ticker QNTM. The company continues to advance its research and development efforts, and the market will be watching for further updates on Lucid-MS and other pipeline assets. For more information on Lucid-MS, visit https://nnw.fm/8uqwL.
